Korean Journal of Microbiology (미생물학회지)

The Microbiological Society of Korea (한국미생물학회)
권호 표지

The Activation of HCV-specific CD8 T Cells by HCV Peptide Pulsed Huh7.5 Cells

Huh7.5 간암 세포주의 HCV 항원제시에 의한 HCV 특이 T 림프구의 활성에 관한 연구

  • Cho, Hyo-Sun (Department of Pharmacy, Duksung Women's University)
  • 조효선 (덕성여자대학교 약학대학 약학과)
  • Received : 2011.11.15
  • Accepted : 2011.12.10
  • Published : 2011.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

T cells play a key role in viral infection. However, in patients with chronic hepatitis C virus (HCV) infection, HCV-specific T cells are dysfunctional and impaired in the liver, which is the primary site for HCV replication. There are multiple potential mechanisms for HCV-specific T cell dysfunction including induction of immune inhibitory pathways (program death-1; PD-1, cytotoxic t lymphocyte associated antigen-4; CTLA-4) and immune tolerance induced specific for the liver. However, the interaction between hepatocytes and HCV-specific CD8 T cells has not clearly established. In this study, we confirmed huh (human hepatoma) 7.5 cells expressing HLA (human leukocyte antigen) A2 presented antigen to activate HCV-specific CD8 T cells in HLA A2-restricted manner and expression of PD-L (program death ligand) 1 on huh7.5 cells reduced HCV-specific CD8 T cell activation, suggesting an immune modulatory activity. Loss of HCV-specific tetramer responses following antigenic stimulation correlated with increased caspase-3 activity. In addition, PD-L1 on huh7.5 cells rescued HCV-specific CD8 T cells from apoptosis. Our results suggest that the interaction between PD-L1 and PD-1 can recover the function of HCV-specific CD8 T cells in the liver, which could be applied in therapy of HCV chronic infection.

인체의 바이러스 감염 방어기전에서 T 림프구는 중요한 역할을 한다. 하지만, 만성 C형 간염 바이러스의 일차적 복제장소인 간염 환자의 간에서 분리된 HCV 특이 T 림프구는 심각한 기능결핍을 보인다. 이러한 T 림프구 기능결핍의 이유로는 PD-1, CTLA-4 등 면역억제 물질의 발현, 또는 간에서 특이적으로 유도되는 면역내성(immune tolerance)이 있으나, 간세포(hepatocytes)와 HCV 특이 T 림프구의 상호작용에 대해서는 명확하게 확립되어 있지 않다. 따라서 본 연구에서는 HLA(human leukocyte antigen) A2+ 간암세포주(human hepatoma cell line; huh7.5)가 항원제시(antigen presentation)를 통해 효과적으로 HCV 특이 T 림프구를 활성화시키며 간암세포주(huh7.5) 표면의 PD-L (program death ligand) 1 발현은 T림프구의 활성을 감소시켜 면역조절의 가능성이 있음을 시사하였다. 또한, HCV 특이 tetramer 반응은 T 림프구의 과도한 활성으로 자기사멸(apoptosis)의 경로에 있음을 caspase 3 활성으로 확인하였고, 역시 PD-L1의 발현이 T 림프구를 자기사멸(apoptosis)로부터 구제하여 caspase 3 활성이 감소하는 것을 확인하였다. 이는 PD-L1과 간성(liver) T 림프구 표면의 PD-1 결합이 T 림프구의 자기사멸을 막고, 또한 그 기능을 회복시켜 만성 C형 간염 치료에 응용될 수 있음을 시사한다.

Keywords

References

  1. Bertolino, P., G.W. McCaughan, and D.G. Bowen. 2002. Role of primary intrahepatic T-cell activation in the 'liver tolerance effect'. Immunol. Cell. Biol. 80, 84-92. https://doi.org/10.1046/j.0818-9641.2001.01048.x
  2. Binder, M., G. Kochs, R. Bartenschlager, and V. Lohmann. 2007. Hepatitis C virus escape from the interferon regulatory factor 3 pathway by a passive and active evasion strategy. Hepatology 46, 1365-1374. https://doi.org/10.1002/hep.21829
  3. Chayama, K., C.N. Hayes, N. Hiraga, H. Abe, M. Tsuge, and M. Imamura. 2011. Animal model for study of human hepatitis viruses. J. Gastroenterol. Hepatol. 26, 13-18. https://doi.org/10.1111/j.1440-1746.2010.06470.x
  4. Freeman, G.J., A.J. Long, and Y. Iwai. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034. https://doi.org/10.1084/jem.192.7.1027
  5. Freeman, G.J., E.J. Wherry, R. Ahmed, and A.H. Sharpe. 2006. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J. Exp. Med. 203, 2223-2227. https://doi.org/10.1084/jem.20061800
  6. Golden-Mason, L., B. Palmer, J. Klarquist, J.A. Mengshol, and N. Castelblanco. 2007. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J. Virol. 81, 9249-9258. https://doi.org/10.1128/JVI.00409-07
  7. Greenwald, R.J., G.J. Freeman, and A.H. Sharpe. 2005. The B7 family revisited. Annu. Rev. Immunol. 23, 515-548. https://doi.org/10.1146/annurev.immunol.23.021704.115611
  8. Holz, L.E., A. Warren, D.G. Le Couteur, D.G. Bowen, and P. Bertolino. 2010. CD8+ T cell tolerance following antigen recognition on hepatocytes. J. Autoimmun. 34, 15-22. https://doi.org/10.1016/j.jaut.2009.08.005
  9. Jo, J., U. Aichele, N. Kersting, R. Klein, P. Aichele, E. Bisse, A.K. Sewell, H.E. Blum, R. Bartenschlager, V. Lohmann, and R. Thimme. 2009. Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology 136, 1391-1401. https://doi.org/10.1053/j.gastro.2008.12.034
  10. Jo, J., V. Lohmann, R. Bartenschlager, and R. Thimme. 2011. Experimental models to study the immunobiology of hepatitis C virus. J. Gen. Virol. 92, 477-493. https://doi.org/10.1099/vir.0.027987-0
  11. Keril, J.B., A.J. McKeating, and M.C. Rice, 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76, 13001-13014. https://doi.org/10.1128/JVI.76.24.13001-13014.2002
  12. Lauer, G.M. and B.D. Walker. 2001. Hepatitis C virus infection. New Engl. J. Med. 345, 41-52. https://doi.org/10.1056/NEJM200107053450107
  13. Nakamoto, N., D.E. Kaplan, J. Coleclough, Y. Li, M.E. Valiga, and K.M. Chang. 2008. Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 134, 1927-1937. https://doi.org/10.1053/j.gastro.2008.02.033
  14. Nakamoto, N., H. Cho, A. Shaked, K. Olthoff, M.E. Valiga, M. Kaminski, E. Gostick, D.A. Price, G.J. Freeman, E.J. Wherry, and K.M. Chang. 2009. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog. 5, e1000313. https://doi.org/10.1371/journal.ppat.1000313
  15. Pagliaro, L., A. Craxi, C. Cammaa, F. Tine, V. di Marco, L. Iacono, and P. Almasio. 1994. Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 19, 820-828.
  16. Salomon, B. and J.A. Bluestone. 2001. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19, 225-252. https://doi.org/10.1146/annurev.immunol.19.1.225
  17. Uebelhoer, L., J.H. Han, B. Callendret, G. Mateu, N.H. Shoukry, H.L. Hanson, C.M. Rice, C.M. Walker, and A. Grakoui. 2008. Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog. 4, e1000143. https://doi.org/10.1371/journal.ppat.1000143
  18. Varela-Rohena, A., C. Carpenito, E.E. Perez, M. Richardson, R.V. Parry, M. Milone, J. Scholler, X. Hao, A. Mexas, R.G. Carroll, C.H. June, and J.L. Riley. 2008. Genetic engineering of T cells for adoptive immunotherapy. Immunol. Res. 42, 166-181. https://doi.org/10.1007/s12026-008-8057-6
  19. Wherry, E.J. and R. Ahmed. 2004. Memory CD8 T-cell differentiation during viral infection. J. Virol. 8, 5535-5545.
  20. Willberg, C., E. Barnes, and P. Klenerman. 2003. HCV immunology-death and the maiden T cell. Cell. Death Differ. 10, S39-47. https://doi.org/10.1038/sj.cdd.4401122